Affordable Access

Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.

Authors
  • Phil Berman
  • Kk, Murthy
  • T, Wrin
  • Jc, Vennari
  • Ek, Cobb
  • Dj, Eastman
  • M, Champe
  • Gr, Nakamura
  • D, Davison
  • Mf, Powell
  • J, Bussiere
  • Dp, Francis
  • T, Matthews
  • Tj, Gregory
  • Jf, Obijeski
Type
Published Article
Journal
The Journal of Infectious Diseases
Publisher
Oxford University Press
Volume
173
Issue
1
Pages
52–59
Source
UCSC Bioinformatics biomedical-ucsc
License
Unknown

Abstract

Three chimpanzees immunized with recombinant gp120 from human immunodeficiency virus type 1 (HIV-1) strain MN and 1 control animal were challenged intravenously with a primary isolate of HIV-1SF2. Viral infection was detected in the control animal by viral culture, polymerase chain reaction, and multiple serologic assays beginning 2 weeks after infection. Markers of HIV-1 infection were not detected in any of the gp120-vaccinated animals during 12 months of follow-up. Antisera from the gp120-immunized chimpanzees were unable to neutralize the challenge virus cultured in peripheral blood mononuclear cells (PBMC). These studies demonstrate that immunization with recombinant gp120 derived from a T cell-adapted isolate prevented infection by a heterologous primary isolate of HIV-1. The results suggest that in vitro virus neutralization assays utilizing primary isolates cultured in PBMC may be imperfect indicators of protection in vivo.

Report this publication

Statistics

Seen <100 times